Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents
These data suggest that current identified broadly neutralizing antibodies could serve as promising drug candidates for COVID-19 and can be used for reverse vaccine design against future pandemics.
Authors
- Caiqin Hu (ORCID: https://orcid.org/0009-0003-2278-8038)
- Li Ren (ORCID: https://orcid.org/0000-0002-0196-4261)
- Junwei Su (ORCID: https://orcid.org/0000-0001-7154-8928)
- Changzhong Jin (ORCID: https://orcid.org/0000-0001-6329-1739)
- Shuo Du (ORCID: https://orcid.org/0000-0003-0936-0785)
- Yiming Shao (ORCID: https://orcid.org/0000-0002-4177-6038)
- Biao Zhu (ORCID: https://orcid.org/0000-0001-6288-4575)
- Junyu Xiao (ORCID: https://orcid.org/0000-0003-1822-1701)
- Dan Li (ORCID: https://orcid.org/0000-0003-2242-9169)
- Shuo Wang (ORCID: https://orcid.org/0000-0002-7990-7515)
- Zheng Wang (ORCID: https://orcid.org/0000-0001-8020-9768)
- Yanling Hao
- Wanqi Ni
- Yi Feng (ORCID: https://orcid.org/0000-0003-4995-1440)
- Ying Zhang (ORCID: https://orcid.org/0000-0001-9900-7568)
- Xinxian Dai
Institutions
- Chinese Center For Disease Control and Prevention (CN)
- Peking University (CN)
- National Vaccine and Serum Institute (CN)
- National Center for AIDS/STD Control and Prevention,China CDC (CN)
- Changzhou University (CN)
- Center for Life Sciences (CN)
- First Affiliated Hospital Zhejiang University (CN)
- State Key Laboratory of Diagnosis and Treatment of Infectious Diseases
- Zhejiang University (CN)
- China National Petroleum Corporation (China) (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1186/s12967-025-06162-6
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- National Natural Science Foundation of China
- State Key Laboratory of Infectious Disease Prevention and Control